{"id":1202,"date":"2007-11-01T12:06:00","date_gmt":"2007-11-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/neue-antidiabetika-uaw-warnung-fuer-byetta-marktruecknahme-von-exubera"},"modified":"2007-11-01T12:06:00","modified_gmt":"2007-11-01T11:06:00","slug":"neue-antidiabetika-uaw-warnung-fuer-byetta-marktruecknahme-von-exubera","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/neue-antidiabetika-uaw-warnung-fuer-byetta-marktruecknahme-von-exubera","title":{"rendered":"Neue Antidiabetika: UAW-Warnung f\u00fcr Byetta\u00ae, Marktr\u00fccknahme von Exubera\u00ae"},"content":{"rendered":"<p>Am 16. Oktober 2007 machte die Food and Drug Administration (FDA, USA) auf 30 Meldungen nach der Zulassung von Byetta\u00ae (Exenatid) \u00fcber das Auftreten akuter Pankreatitiden bei Anwendern dieses s.c. zu injizierenden Analogons von Glucagon-like peptide aufmerksam (1). Wir haben k\u00fcrzlich \u00fcber das neue Antidiabetikum, das die Insulinsekretion bei Typ-2-Diabetikern stimuliert, berichtet (2). In mehreren [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Am 16. Oktober 2007 machte die Food and Drug Administration (FDA, USA) auf 30 Meldungen nach der Zulassung von Byetta\u00ae (Exenatid) \u00fcber das Auftreten akuter Pankreatitiden bei Anwendern dieses s.c. zu injizierenden Analogons von Glucagon-like peptide aufmerksam (1). Wir haben k\u00fcrzlich \u00fcber das neue Antidiabetikum, das die Insulinsekretion bei Typ-2-Diabetikern stimuliert, berichtet (2). In mehreren [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[155,2822,50,2598],"class_list":["post-1202","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-diabetes-mellitus-typ-2","tag-exenatid","tag-insulin","tag-pankreatitis"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1202"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1202\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}